 |
1 Product |  |
0 Diseases | | 1 Product |
|
1 Trial |  |
18 News |  |
- Begedina (begelomab) / Adienne
Begelomab Salvages Steroid Resistant Acute Graft Versus (SR aGVHD) Host Disease in Pediatric Patients: A Single Center Case Serie () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1046;
Here, we present our experience with pediatric patients who received Begelomab for SR aGvHD. Five patients (3-20 years) received Begelomab for SR aGVHD at Stanford Children's Health from 2017 to 2021 (IRB#4134, 46969).
- | Begedina (begelomab) / Biotec Pharmacon, Adienne, Regkirona (regdanvimab) / Celltrion
Journal: Designing of a bispecific antibody against SARS-CoV-2 spike glycoprotein targeting human entry receptors DPP4 and ACE2. (Pubmed Central) - Apr 12, 2022
Also, for blocking the primary entry receptor, hACE2, an anti-viral peptide was linked to the Fc region of BsAb that blocks the hACE2 receptor by linker cleavage inside the infected host. Thus, the designed BsAb and anti-viral peptide therapy could be a promising triumvirate way to obstruct the viral entry by blocking the receptor engagement.
- | Begedina (begelomab) / Biotec, Adienne
Journal: Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody-Begelomab. (Pubmed Central) - Jun 22, 2021
P2
The overall survival at 1 year was 50% for the prospective studies and 33% for the compassionate use patients. In conclusion, Begelomab induces over 60% responses in SR-aGvHD, including patients with severe gut and liver GvHD, having failed one or more lines of treatment.
- || Begedina (begelomab) / Biotec, Adienne
Clinical, Journal: Begelomab for severe refractory dermatomyositis: A case report. (Pubmed Central) - Mar 10, 2021
In conclusion, Begelomab induces over 60% responses in SR-aGvHD, including patients with severe gut and liver GvHD, having failed one or more lines of treatment. Blockade of DPP-4/CD26, which is expressed on T cells and mediates T cell activation and function, is safe and might be effective in patients with refractory DM.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Entyvio (vedolizumab) / Takeda
[VIRTUAL] Efficacy and Toxicity Profile of Investigational Monoclonal Antibodies for the Treatment of Acute Gvhd () - Nov 5, 2020 - Abstract #ASH2020ASH_5396;
Responses appear to be related to the duration and timing of the therapy, GVHD severity, organ involvement, and the number of previous lines of therapy received. Large prospective clinical trials are needed to further solidify the role of monoclonal antibodies in aGVHD treatment.
- Venclexta (venetoclax) / Roche, AbbVie
[VIRTUAL] Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Immunolipsome Loaded Venetoclax (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1014;
Liposomes are suitable carriers because of their biocompatibility, self-assembly, large drug payload, and minimal toxicity. This strategy may help us to increase the number of patients attaining and maintaining TFR without relapsing.
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Journal: The CoV-2 outbreak: how hematologists could help to fight Covid-19. (Pubmed Central) - Jul 1, 2020
We also present immunological data from gene expression experiments where TKIs resulted effective anti-inflammatory and pro-immune drugs. A possible combined treatment algorithm for COVID-19 is here proposed.
- | ADN-LYS / Adienne
Journal: An optimised method for the rapid analysis of condensed phosphates in fishery and processed marine food products using ion chromatography and microwave sample processing. (Pubmed Central) - Mar 5, 2020
Especially, we identified that phosphate levels in the processed shrimp and dried shredded squid samples exceeded the maximum allowable levels specified in the CODEX standard. We believe that our method would be useful for the rapid analysis of condensed phosphates in various types of fishery and processed marine food products.
- Begedina (begelomab) / Adienne
Trial termination, Trial primary completion date, IO biomarker: Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD (clinicaltrials.gov) - Sep 21, 2017
P3, N=36, Terminated, Sponsor: Adienne SA
We believe that our method would be useful for the rapid analysis of condensed phosphates in various types of fishery and processed marine food products. Active, not recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Jul 2017; Insufficient rate of accrual
- | Begedina (begelomab) / Adienne
Enrollment closed, Enrollment change, IO biomarker: Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD (clinicaltrials.gov) - Jun 22, 2017
P3, N=36, Active, not recruiting, Sponsor: Adienne SA
Active, not recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Jul 2017; Insufficient rate of accrual Recruiting --> Active, not recruiting | N=184 --> 36
- |||||| Begedina (begelomab) / Adienne
Enrollment open, IO biomarker: Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD (clinicaltrials.gov) - Jun 19, 2016
P3, N=184, Recruiting, Sponsor: Adienne SA
Recruiting --> Active, not recruiting | N=184 --> 36 Not yet recruiting --> Recruiting
- | Begedina (begelomab) / Adienne
Trial initiation date, Trial primary completion date, IO biomarker: Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD (clinicaltrials.gov) - Jul 15, 2015
P3, N=184, Not yet recruiting, Sponsor: Adienne SA
Not yet recruiting --> Recruiting Initiation date: Sep 2015 --> Jan 2016 | Trial primary completion date: Sep 2017 --> Feb 2018
- || Begedina (begelomab) / Adienne
New P3 trial, IO biomarker: Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD (clinicaltrials.gov) - Apr 8, 2015
P3, N=186, Not yet recruiting, Sponsor: Adienne SA